Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies. J of Skin [Internet]. 2020 Sep. 2 [cited 2025 Apr. 19];4(5):s42. Available from: https://skin.dermsquared.com/skin/article/view/991